News

AstraZeneca’s Xigduo now available in Mauritius

AstraZeneca’s Xigduo now available in Mauritius

AstraZeneca, a global, science-led, biopharmaceutical company is pleased to announce the launch of XIGDUO™ XR
in Mauritius.

XIGDUO™ XR is a combination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and metformin, a biguanide.1 This once-daily oral hypoglycaemic combination is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes when treatment with both dapagliflozin and metformin is appropriate.

Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
  • Image
  • SKU
  • Rating
  • Price
  • Stock
  • Availability
  • Add to cart
  • Description
  • Content
  • Weight
  • Dimensions
  • Additional information
  • Attributes
  • Custom attributes
  • Custom fields
Click outside to hide the compare bar
Compare
Wishlist 0
Open wishlist page Continue shopping